ABSTRACT
Objective To test comparative effect of capecitabine and S-1 (Tegafur/gimeracil/oteracil) on advanced colorectal cancer.Methods 106 cases of advanced colorectal cancer in our hospital oncology were collected and randomly divided into 2 groups:capecitabine group (52 cases) and S-1 group (54 cases).The chemotherapy effect and adverse effect of 2 groups were collected.Results After one treatment period,3 cases of complete remission,19 cases of partial remission,15 cases of stable disease,15 cases of disease progression,efficient rate of 42.3％and control rate of 71.2％ were observed in capecitabine group.5 cases of complete remission,21cases of partial remission,19 cases of stable disease,9 cases of disease progression and efficient rate of 48.1％ and control rate of 83.3％ were observed in S-1 group.There were no significant differences in efficient rate,control rate adverse effect rate and survival time between 2 groups(P ＞ 0.05).Conclusion Capecitabine and S-1 are both safe and effective in treatment of advanced colorectal cancer.
ABSTRACT
Objective To study the angiogenesis in serous ovarian neoplasms. Methods Immunohistochemical method was used to examine microvessei density (MVD) and the expressions of vascular endothelial growth factor (VEGF) in 76 cases of serous ovarian neoplasm. The relationship between MVD and VEGF were investigated. Results MVD in the tissues of cystadenoma, bordline cystadenoma and cystadenocarcinoma were 7.8±2.4, 17.5±3.3 and 27.6±7.5; VEGF expressions were (16.1±3.9)%, (36.7±14.2)%, (52.3±22.8)%; the differences were significant respectively. Of cystadenocarcinoma grade 1, grade 2 and grade 3, MVD were 18.3+3.4, 24.2±3.1, and 32.3±6.4, VEGF expressions were (30.9±16.2)%, (48.0±18.4) % and (62.1±21.3) %, the differences were significant respectively. Of FIGO stage Ⅲ～Ⅳ and stage Ⅰ～Ⅱ, MVD were 28.9±4.7 and 22.0±4.7, VEGF expressions were (55.1±22.9) % and (40.18±18.0) %, the differences were significant respectively. There was significant positive correlation between VEGF expression and MVD. Conclusion Angiogenesis is very important in the development of serous ovarian neoplasms.
ABSTRACT
Objective To evaluate the short-term effects of methotrexate (MTX) injection by hysteroscopic tubal catheterization for unruptured tubal pregnancy, and to investigate factors influencing curative effects of such approach. Methods A total of 82 patients with unruptured tubal pregnancy underwent injection of MTX 20 mg (10ml) by hysteroscopic tubal catheterization from October 2000 to September 2002. Clinical efficiency and side effects were recorded. After administration for 72 hours, in case serum ?-HCG level had dropped less than 50 percent, a second injection of MTX was given. Results The total cure rate was 82.9% (68/82), and 72.0% (59/82) of the patients were cured clinically with the first administration of MTX, with the length of hospitalization being (10?4.9) days. Statistically, the drug reflux at injection, the declining level of ?-HCG after administration, and the serum level of ?-HCG ≥ 4000 mIu/ml before administration significantly influenced the curative effects (P=0.000, P=0.001, P=0.032, respectively). No side effects were found in this study. Out of the 65 cured patients followed up for 2 months,57 (87.7%) got normal menstruation. Conclusions MTX injection by hysteroscopic tubal catheterization for unruptured tubal pregnancy is effective, simple, minimally invasive and safe.